← 返回

胰腺导管腺癌患者中 CD3(+) 与 CD8(+) TIL(肿瘤浸润淋巴细胞)(TILs) 与预后的关联

英文原题:The association between CD3(+) and CD8(+)tumor-infiltrating lymphocytes (TILs) and prognosis in patients with pancreatic adenocarcinoma.

查看英文原题

The association between CD3(+) and CD8(+)tumor-infiltrating lymphocytes (TILs) and prognosis in patients with pancreatic adenocarcinoma.

PubMed 2023/03/25(内容时间) Cancer Treat Res Commun Q2 · IF 3.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

胰腺导管腺癌患者的 TILs 密度高。

中文摘要

胰腺导管腺癌(PDAC)每年造成超过25万人死亡,全球死亡原因中居第八位,5年生存率低于5%,中位复发时间为5至23个月。近期研究显示CD3/CD8阳性TIL(肿瘤浸润淋巴细胞)与肿瘤播散和临床结局相关。本研究旨在测定PDAC患者TIL密度并分析其与预后的关系。

收集64例TIL阳性PDAC患者肿瘤及邻近正常组织,以免疫组化检测CD3和CD8阳性TIL,并完成至少5年随访。

肿瘤内和肿瘤周围TIL分别见于20例(31.2%)和44例(68.8%)。CD3和CD8阳性TIL平均密度分别为67.73%和69.45%。其密度与总生存期、无转移生存及肿瘤分级无关;但复发患者的TIL密度显著低于未复发者。

PDAC患者TIL密度总体较高,复发患者CD3和CD8阳性TIL密度较低,监测其密度可能有助于预测复发。

展开英文摘要原文

Pancreatic adenocarcinoma (PDAC), with more than 250,000 deaths each year, is the eighth leading cause of death worldwide, with a five-year survival of less than 5% and a median recurrence time between 5 and 23 months. The association between PDAC and CD3 + /CD8 + tumor-infiltrating lymphocytes (TILs) and the extent of tumor spread and clinical outcomes has been recently shown. This study aimed to determine and compare the density of TILs and their association with disease prognosis in patients with PDAC.

In this study, we collected PDAC tissues and corresponding adjacent normal tissues from 64 patients with TIL-positive PDAC. The immunohistochemistry method was used for the detection of the expression levels of CD3 + and CD8 + TILs in PDAC tissues. Also, the completed follow-up history was evaluated for at least five years.

The frequency of intratumoral and peritumoral TILs was 20 (31.2%) and 44 (68.8%), respectively. The mean density of CD3 + TILs and CD8 + TILs was 67.73% 20.17% and 69.45% 17.82%, respectively. The density of CD3 + TILs and CD8 + TILs was not associated with overall survival nor metastasis-free survival of the patients and tumor grade. However, the density of TILs was significantly lower in those patients who experienced tumor recurrence than those without this recurrence.

TILs density was high in patients with PDAC. The density of both CD3 + and CD8 + TILs was significantly lower in patients who experienced tumor recurrence. Thus, this study suggests that tracking and determining the density of CD3 + and CD8 + TILs might be effective in predicting PDAC recurrence.

论文信息

作者
Panahi M、Rezagholizadeh F、Mollazadehghomi S、Farhangnia P、Niya MHK、Ajdarkosh H、Tameshkel FS、Heshmati SM
第一作者单位
Gastrointestinal and Liver Diseases Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.Iran
通讯作者单位
Gastrointestinal and Liver Diseases Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Department of Pathology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Electronic address: Mooe_360@yahoo.com.Iran
文献类型
非美国政府资助研究
期刊
Cancer treatment and research communications2023
原文标识
PubMed 36996584 · DOI 10.1016/j.ctarc.2023.100699